// App-Quantinova.ai

: Off-the-Shelf Natural Killer Cells with Multi-Functional Engineering Using a Novel Anti-CD19 Chimeric Antigen Receptor Combined with Stabilized CD16 and IL15 Expression to Enhance Directed Anti-Tumor Activity

Researchers

Presenter

  • Dan S Kaufman

Principal Investigators

  • Ryan Bjordahl

  • Huang Zhu

  • Robert Blum

  • Andres Bahena

  • Sajid Mahmood

  • Greg Bonello

  • Tom Lee

  • Bruce Walcheck

  • Frank Cichocki

  • Jeffrey S. Miller

  • Bahram Valamehr

Medical Centers

  • Division of Regenerative Medicine, University of California San Diego, La Jolla, CA

  • Mirati Therapeutics Inc., San Diego, CA

  • Division of Regenerative Medicine, University of California San Diego, La Jolla, CA

  • Mirati Therapeutics Inc., San Diego, CA

  • Mirati Therapeutics Inc., San Diego, CA

  • University of Minnesota, Minneapolis, MN

  • Division of Hematology Oncology and Transplantation, University of Minnesota, Minneapolis, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

  • Cytokine release syndrome

Biomarkers

  • Cluster of differentiation 45

  • Cluster of Differentiation 56

  • Fc gamma RIIIa

  • Interleukin-15

  • Interleukin-2

  • Twist-related protein 1

  • Natural killer group 2D

Drug/Treatment

  • IL-15

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved